-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
U 18666A
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/3039-71-2.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 3039-71-2 |
| Description | U 18666A is a cell-permeable and amphiphilic amino-steroid that inhibits cholesterol synthesis and cellular transport via the suppression of 2,3-oxidosqualene-lanosterol cyclase activity. U 18666A also acts as a weak inhibitor of hedgehog (Hh) signaling. It has been shown to reduce serum sterol levels in rats in vivo. |
Product Information
| Synonyms | U-18666A; U 18666A; U18666A; U 18666 A; U-18666-A; NSC-70801; NSC 70801; NSC70801; (3β)-3-[2-(Diethylamino)ethoxy]androst-5-en-17-one hydrochloride |
| Molecular Weight | 424.07 |
| Molecular Formula | C25H41NO2.HCl |
| Canonical SMILES | CCN(CC)CCOC1CCC2(C3CCC4(C(C3CC=C2C1)CCC4=O)C)C.Cl |
| InChI | InChI=1S/C25H41NO2.ClH/c1-5-26(6-2)15-16-28-19-11-13-24(3)18(17-19)7-8-20-21-9-10-23(27)25(21,4)14-12-22(20)24;/h7,19-22H,5-6,8-17H2,1-4H3;1H/t19-,20-,21-,22-,24-,25-;/m0./s1 |
| InChIKey | GZFYZYBWLCYBMI-MYZJJQSMSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | In Vitro: 10 mM in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | -20°C, stored under nitrogen * In solvent : -80°C 6 months -20°C 1 month (stored under nitrogen) |
| Complexity | 624 |
| Exact Mass | 423.2904073 |
| In Vitro | U18666A, the antiviral effect is found to result from two events: retarded viral trafficking in the cholesterol-loaded late endosomes/lysosomes and suppresse de novo sterol biosynthesis in treated infected cells. It is also observed an additive antiviral effect of U18666A with C75, a fatty acid synthase inhibitor, suggesting dengue virus relies on both the host cholesterol and fatty acid biosynthesis for successful replication. |
| PSA | 29.54000 |
| Target | HCV |